SOURCE: SciClone Pharmaceuticals, Inc.

March 13, 2007 14:28 ET

SciClone Pharmaceuticals to Report Fourth Quarter and Year End Results on March 15, 2007

SAN MATEO, CA -- (MARKET WIRE) -- March 13, 2007 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report fourth quarter and year end 2006 results and host a conference call on Thursday, March 15, 2007.

The conference call will contain forward-looking statements. Financial and statistical information to be discussed on the call will be posted on the Investor Relations section of SciClone's website at prior to the commencement of the conference call.

DATE:               Thursday, March 15, 2007
TIME:               10:00 a.m. ET (7:00 a.m. PT)
WEBCAST:            Live call and replay accessible at
LIVE CALL:          888-515-2235 (U.S./Canada)
                    719-457-2601 (International)
REPLAY:             888-203-1112 (U.S./Canada)
                    719-457-0820 (International)
                    Passcode:  8233644
                    (Replay available from 1:00 p.m. ET on March 15, 2007
                    through 12:00 a.m. ET on April 25, 2007)
About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage in China by in-licensing or acquiring the marketing rights to other products, such as the DC Bead, to broaden its portfolio in this rapidly growing pharmaceutical market. SciClone's other drug development candidate is SCV-07, currently in early clinical development in the U.S. for the treatment of viral infectious diseases. For more information about SciClone, visit

Contact Information

  • Corporate contact:
    Richard Waldron
    Executive Vice President and Chief Financial Officer
    SciClone Pharmaceuticals, Inc.